SAFETY DATA FROM AN EXPANDED ACCESS PROGRAM (EAP) OF NIVOLUMAB (NIVO) IN COMBINATION WITH IPILIMUMAB (IPI) IN PATIENTS WITH ADVANCED MELANOMA (MEL)

被引：0
|
作者：
Chapman, Paul B. [1 ]
Sznol, Mario [2 ]
Lao, Christopher D. [3 ]
Gonzalez, Rene [4 ]
Daniels, Gregory A. [5 ]
Thompson, John A. [6 ]
Kudchadkar, Ragini R. [7 ]
Sharfman, William H. [8 ]
Atkins, Michael B. [9 ]
Pavlick, Anna C. [10 ]
Infante, Jeffrey R. [11 ]
Kim, Kevin B. [12 ]
Weber, Jeffrey S. [13 ]
Nair, Suresh [14 ]
Cowey, Lance [15 ]
Lipson, Evan J. [8 ]
Lee, Sue [16 ]
Avila, Alexandre [16 ]
Hodi, Stephen [17 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] Yale Canc Ctr, New Haven, CT USA
[3] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA
[4] Univ Colorado, Ctr Canc, Denver, CO 80262 USA
[5] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA
[6] Univ Washington, Seattle, WA 98195 USA
[7] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[8] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA
[9] Georgetown Lombardi Comprehens Canc Ctr, Washington, DC USA
[10] NYU, New York, NY USA
[11] Tennessee Oncol PLLC, Sarah Cannon Res Inst, Nashville, TN USA
[12] Calif Pacific Ctr Melanoma Res, San Francisco, CA USA
[13] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[14] Lehigh Valley Hosp, Allentown, PA USA
[15] Texas Oncol Baylor Charles A Sammons Canc Ctr, Dallas, TX USA
[16] Bristol Myers Squibb, Princeton, NJ USA
[17] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 12卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
219
引用
收藏
页码：119 / 119
页数：1
相关论文
共 50 条
  • [31] UPDATED RESULTS FROM A PHASE 3 TRIAL OF NIVOLUMAB (NIVO) COMBINED WITH IPILIMUMAB (IPI) IN TREATMENT-NAIVE PATIENTS WITH ADVANCED MELANOMA (MEL) (CheckMate 067)
    Wolchok, Jedd D.
    Chiarion-Sileni, Vanna
    Gonzalez, Rene
    Rutkowski, Piotr
    Grob, Jean-Jacques
    Cowey, C. Lance
    Lao, Christopher D.
    Schadendorf, Dirk
    Ferrucci, Pier F.
    Smylie, Michael
    Dummer, Reinhard
    Hill, Andrew
    Haanen, John
    Maio, Michele
    McArthur, Grant
    Walker, Dana
    Jiang, Joel
    Horak, Christine
    Larkin, James
    Hodi, Stephen
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 : 127 - 128
  • [32] Management of gastrointestinal (GI) toxicity associated with nivolumab (NIVO) plus ipilimumab (IPI) or IPI alone in phase II and III trials in advanced melanoma (MEL).
    Weber, Jeffrey S.
    Larkin, James M. G.
    Schadendorf, Dirk
    Wolchok, Jedd D.
    Wagstaff, John
    Dummer, Reinhard
    Hogg, David
    Guidoboni, Massimo
    Sosman, Jeffrey Alan
    Chmielowski, Bartosz
    Gerritsen, Winald
    Bhore, Rafia
    Walker, Dana
    Gonzalez, Rene
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [33] Efficacy and safety results from a phase III trial of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067).
    Wolchok, Jedd D.
    Chiarion-Sileni, Vanna
    Gonzalez, Rene
    Rutkowski, Piotr
    Grob, Jean Jacques
    Cowey, Charles Lance
    Lao, Christopher D.
    Schadendorf, Dirk
    Ferrucci, Pier Francesco
    Smylie, Michael
    Dummer, Reinhard
    Hill, Andrew Graham
    Haanen, John B. A. G.
    Maio, Michele
    McArthur, Grant A.
    Yang, Arvin
    Rollin, Linda
    Horak, Christine E.
    Larkin, James M. G.
    Hodi, F. Stephen
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [34] Efficacy and safety of nivolumab (NIVO) in patients with advanced melanoma (MEL) and poor prognostic factors who progressed on or after ipilimumab (IPI): Results from a phase II study (CheckMate 172).
    Schadendorf, Dirk
    Ascierto, Paolo Antonio
    Haanen, John B. A. G.
    Espinosa, Enrique
    Demidov, Lev V.
    Garbe, Claus
    Lorigan, Paul
    Gogas, Helen
    Hoeller, Christoph
    Guren, Tormod Kyrre
    Rorive, Andree
    Rutkowski, Piotr
    Munoz-Couselo, Eva
    Dummer, Reinhard
    Carneiro, Ana
    Hospers, Geke
    Grigoryeva, Elena Borisovna
    Bhore, Rafia
    Nathan, Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [35] Efficacy and safety results from a phase III trial of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067)
    Wolchok, Jedd D.
    Chiarion-Sileni, Vanna
    Gonzalez, Rene
    Rutkowski, Piotr
    Grob, Jean Jacques
    Cowey, Charles Lance
    Lao, Christopher D.
    Schadendorf, Dirk
    Ferrucci, Pier Francesco
    Smylie, Michael
    Dummer, Reinhard
    Hill, Andrew Graham
    Haanen, John B. A. G.
    Maio, Michele
    McArthur, Grant A.
    Yang, Arvin
    Rollin, Linda
    Horak, Christine E.
    Larkin, James M. G.
    Hodi, F. Stephen
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (18)
  • [36] EFFICACY AND SAFETY DATA FROM PATIENTS WITH ADVANCED MELANOMA AND BRAIN METASTASES PARTICIPATING IN THE EUROPEAN IPILIMUMAB EXPANDED ACCESS PROGRAMME (EAP) IN ITALY
    Queirolo, P.
    Simeone, E.
    De Galitiis, F.
    Di Guardo, L.
    Di Giacomo, A. M.
    Marconcini, R.
    Ferraresi, V.
    De Rosa, F.
    Guida, M.
    Stragliotto, S.
    ANNALS OF ONCOLOGY, 2012, 23 : 369 - 369
  • [37] Age-dependent Efficacy and Safety of Nivolumab (NIVO) as Monotherapy or Combination Therapy with Ipilimumab (NIVO plus IPI) in Patients with advanced Melanoma in the non-interventional Study (NIS) NICO
    Schadendorf, D.
    Ugurel, S.
    Eigentler, T.
    Mohr, P.
    Wei-Chenthal, M.
    Gebhardt, C.
    Goppner, D.
    Haferkamp, S.
    Herbst, R.
    Kahler, K.
    Kreuter, A.
    Meier, F.
    Pfohler, C.
    Sachse, M. M.
    Sickmann, T.
    Terheyden, P.
    Ulrich, J.
    Utikal, J. S.
    Grimmel-Mann, I.
    Gutzmer, R.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2021, 19 : 16 - 17
  • [38] Overall Survivalwith Nivolumab (NIVO) and Ipilimumab (IPI) Combination Therapy in a Phase III Trial of Advanced Melanoma (CHECKMATE 067)
    Larkin, J.
    Chiarion-Sileni, V.
    Gonzalez, R.
    Rutkowski, P.
    Grob, J-J
    Cowey, C. L.
    Lao, C. D.
    Schadendorf, D.
    Ferrucci, P. F.
    Smylie, M.
    Dummer, R.
    Hill, A.
    Haanen, J.
    Maio, M.
    McArthur, G.
    Walker, D.
    Rollin, L.
    Horak, C.
    Hodi, F. S.
    Wolchok, J. D.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 48 - 48
  • [39] CLINICAL RESPONSE, PROGRESSION-FREE SURVIVAL (PFS) AND SAFETY IN PATIENTS (PTS) WITH ADVANCED MELANOMA (MEL) RECEIVING NIVOLUMAB (NIVO) COMBINED WITH IPILIMUMAB (IPI) VERSUS IPI MONOTHERAPY IN CHECKMATE 069 STUDY
    Hodi, F. Stephen
    Postow, Michael A.
    Chesney, Jason
    Pavlik, Anna C.
    Robert, Caroline
    Grossman, Kenneth
    McDermott, David
    Linette, Gerald
    Meyer, Nicolas
    Giguere, Jeffrey K.
    Agarwala, Sanjiv S.
    Shaheen, Montaser
    Ernstoff, Marc S.
    Minor, David
    Salama, April K.
    Taylor, Matthew
    Ott, Patrick A.
    Horak, Christine
    Gagnier, Paul
    Wolchok, Jedd D.
    Asia-Pacific Journal of Clinical Oncology, 2015, 11 : 109 - 109
  • [40] Italian nivolumab Expanded Access Program (EAP) in melanoma adjuvant setting: Patients outcomes and safety profile
    Del Vecchio, M.
    Di Giacomo, A. M.
    Quaglino, P.
    Sileni, V. Chiarion
    Queirolo, P.
    De Galitiis, F.
    Cognetti, F.
    Mandala', M.
    Guidoboni, M.
    Rinaldi, G.
    Depenni, R.
    Consoli, F.
    Troiani, T.
    Guida, M.
    Marconcini, R.
    Ferrucci, P. F.
    Bersanelli, M.
    Rossi, E.
    Aglietta, M.
    Ascierto, P. A.
    ANNALS OF ONCOLOGY, 2021, 32 : S890 - S891
12345